Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
Express Scripts
Cipla
Chinese Patent Office
Citi
McKesson
Moodys
Cerilliant

Generated: February 17, 2019

DrugPatentWatch Database Preview

Valeant Pharms North Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS NORTH, and what generic alternatives to VALEANT PHARMS NORTH drugs are available?

VALEANT PHARMS NORTH has twenty-four approved drugs.

There are ten US patents protecting VALEANT PHARMS NORTH drugs.

There are fifty-one patent family members on VALEANT PHARMS NORTH drugs in seventeen countries and twenty-one supplementary protection certificates in eleven countries.

Summary for Valeant Pharms North
International Patents:51
US Patents:10
Tradenames:22
Ingredients:19
NDAs:24

Drugs and US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-001 Apr 23, 2008 RX Yes No 7,645,802 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 DISCN Yes No ➤ Sign Up ➤ Sign Up
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes 7,662,407 ➤ Sign Up Y ➤ Sign Up
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-003 Sep 11, 1995 AB4 RX Yes No ➤ Sign Up ➤ Sign Up
Valeant Pharms North NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 075289-001 Sep 27, 2000 AB2 RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-002 Sep 11, 1995 6,162,463 ➤ Sign Up
Valeant Pharms North DIASTAT diazepam GEL;RECTAL 020648-005 Jul 29, 1997 5,462,740 ➤ Sign Up
Valeant Pharms North RENOVA tretinoin CREAM;TOPICAL 019963-001 Dec 29, 1995 RE36068 ➤ Sign Up
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-006 Oct 16, 1998 6,162,463 ➤ Sign Up
Valeant Pharms North TIAZAC diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020401-006 Oct 16, 1998 5,529,791 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT PHARMS NORTH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24

Supplementary Protection Certificates for Valeant Pharms North Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00043 Netherlands ➤ Sign Up PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
2017 00062 Denmark ➤ Sign Up PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330
C0021 Belgium ➤ Sign Up PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
2013025,C1304992 Lithuania ➤ Sign Up PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
13/044 Ireland ➤ Sign Up PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cerilliant
Harvard Business School
Federal Trade Commission
Boehringer Ingelheim
Julphar
QuintilesIMS
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.